Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Individual and Combined Endothelin Receptor and SGLT2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial

Next Previous
Trial Profile

Individual and Combined Endothelin Receptor and SGLT2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary) ; SC-0062 (Primary)
  • Indications Renal failure; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ASPIRE-1

Most Recent Events

  • 07 Oct 2025 Protocol amended to remove Ambrisentan Sotagliflozin and dApagliflozin SC0062 drugs were added.
  • 07 Oct 2025 Planned End Date changed from 1 Dec 2027 to 1 Dec 2028.
  • 07 Oct 2025 Planned primary completion date changed from 1 Sep 2027 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top